Clinical trials: Schizophrenia Diagnosis
Ultra High Risk for Psychosis
Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe
The purpose of this study is to determine whether omega-3 fatty acids are effective in the prevention of psychosis in individuals at ultra-high risk for psychosis.
- Trial name
- PURPOSE (NCT02597439)
- Testing
- Omega-3 fatty acids
- Where
- 14 sites in Austria, Germany and 7 more
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Rene Kahn
Schizophrenia
Integrated Supported Employment in Mainland China
In this randomized controlled trial, the researchers investigated the effectiveness of integrated supported employment (ISE) as compared with individual placement and support (IPS) and traditional vocational rehabilitation (TVR)…
- Trial name
- NCT03273530
- Testing
- Integrated Supported Employment
- Volunteers
- 162 people
- Sponsor
- The Hong Kong Polytechnic University
Healthy Volunteers, Schizophrenia
Effects of Ketamine and Risperidone on Cognition
The primary objective of this study is: To determine the effects of ketamine, which blocks the ion-channel gated by the NMDA receptor, on performance of cognitive tasks and the extent to which these effects can be reversed by the…
- Trial name
- Schiz_2 (NCT01140620)
- Testing
- ketamine, risperidone, saline
- Where
- 3 sites in United Kingdom
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Schizophrenia
A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)
This randomized, multi-center, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia.
- Trial name
- NCT01235520
- Testing
- RO4917838
- Where
- 121 sites in United States, Argentina and 12 more
- Volunteers
- 595 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia and Related Disorders
Tele-group Cognitive Behavioural Family Intervention for Individuals With Schizophrenia and Their Families (Definitive tgCBFI)
This mixed-method study comprises a RCT with a twelve-week post-intervention follow-up and focus group interviews. The RCT study aims to examine the effectiveness of delivering the tgCBFI programme to dyads of people with…
- Trial name
- NCT07121166
- Testing
- tgCBFI programme, Treatment as Usual (TAU)
- Where
- 6 sites in Hong Kong
- Volunteers
- 200 people
- Sponsor
- The Hong Kong Polytechnic University
Schizophrenia
Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia
The purpose of this study is to explore changes in efficacy, cognitive functioning, and safety of flexibly-dosed Brexpiprazole monotherapy in subjects with acute schizophrenia
- Trial name
- NCT02054702
- Testing
- Brexpiprazole, Aripiprazole
- Volunteers
- 97 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
- Trial name
- ARRIVE- EU (NCT01509053)
- Testing
- Aripiprazole (Abilify®) IM Depot Injection, Oral aripiprazole
- Where
- 10 sites in Belgium, Bulgaria and 1 more
- Volunteers
- 30 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia Disorders, Personality Disorders
Recovery in Telling Life Stories
This project tests the Recovery In Telling Life Stories (RETELL) intervention, aimed at supporting personal recovery in people with severe mental illness (SMI).
- Conditions
- Schizophrenia Disorders, Personality Disorders, Obsessive - Compulsive Disorder, Anxiety Disorders
- Trial name
- RETELL (NCT07082777)
- Testing
- Narrative therapy
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- University of Aarhus
Schizophrenia, Drug Abuse/Dependency
Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence
Background: Individuals with schizophrenia have a significantly higher tendency to develop substance abuse or dependence than the general population.
- Trial name
- NCT01037075
- Where
- 2 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Schizophrenia, Impaired Cognition
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.
- Trial name
- NCT01716975
- Testing
- EVP-6124
- Where
- 106 sites in United States, Argentina and 10 more
- Volunteers
- 767 people
- Sponsor
- FORUM Pharmaceuticals Inc
Autism Spectrum Disorder, Depression - Major Depressive Disorder
Mental Health, Intellectual and Neurodevelopmental Disorder Detection With Artificial Intelligence Models
This study investigates whether AI-driven analysis of speech can accurately predict clinical diagnoses and assess risk for various mental or behavioral health conditions, including attention-deficit/hyperactivity disorder (ADHD)…
- Conditions
- Autism Spectrum Disorder, Depression - Major Depressive Disorder, Anxiety, Generalized, Bipolar Disorder (BD)
- Trial name
- MINDAIM (NCT06792175)
- Testing
- Solicue Machine Learning Models, Mercuria Machine Learning Models
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- Psyrin Inc.
Schizophrenia, Schizoaffective Disorder
Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders
The investigators propose to recruit individuals with schizophrenia who are symptomatically stable and already taking medications to participate in this study.
- Trial name
- NCT01519557
- Testing
- DAR-100A
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- New York State Psychiatric Institute
Psychotic Disorders, Family Members
Supporting Patients by Family Education in Psychotic Illness: A Prospective Cohort Study
Background: A lack of education, resources, and support for family carers of young adults with psychotic illnesses leaves them ill-equipped to support their loved one.
- Conditions
- Psychotic Disorders, Family Members, Anosognosia, Paranoia
- Trial name
- NCT05500001
- Testing
- Supporting Patients by Family Education in Psychotic Illness Group
- Where
- 4 sites in Canada
- Volunteers
- 113 people
- Sponsor
- University of Alberta
Schizophrenia
Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia
A Multicentre, Open-label, Prospective Long-term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR® (Quetiapine Fumarate Extended-Release Tablets) in Subjects with Schizophrenia.
- Trial name
- SPECTRUM (NCT00640601)
- Testing
- Quetiapine Fumarate Extended- Release
- Where
- 36 sites in Australia, Canada and 2 more
- Volunteers
- 331 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorder
Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia
Smokers with schizophrenia have more difficulties quitting smoking than smokers without a mental disorder. Varenicline (Champix) is a new stop smoking medication with a unique mechanism of action.
- Trial name
- NCT01093365
- Testing
- Varenicline
- Where
- Canada
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
52-week Open Label Safety-Tolerability Study
Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia
- Trial name
- NOVA3 (NCT07369154)
- Testing
- LB-102
- Where
- 23 sites in United States
- Volunteers
- 900 people
- Sponsor
- LB Pharmaceuticals Inc.
Major Depressive Disorder, Bipolar Disorder
Venous Tourniquet vs. Arterial Tourniquet for Seizure Monitoring in ECT
This prospective, open-label clinical trial aims to compare a novel "Venous Tourniquet with Regional Low-Dose Sugammadex" method against the gold standard "Arterial Tourniquet" (Isolated Forearm Technique - IFT) for monitoring…
- Conditions
- Major Depressive Disorder, Bipolar Disorder, Schizophrenia
- Trial name
- NCT07534475
- Testing
- Device: Arterial Tourniquet, Device: Venous Tourniquet, Sugammadex
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Medipol University
Schizophrenia Disorder
KetoBrain: Brain Energy Metabolism in Schizophrenia
Objective The objective is to recruit antipsychotic-naïve patients at the first diagnosis with a first-episode schizophrenia disorder (FES) to study ketone metabolism of the brain via PET neuroimaging.
- Trial name
- NCT07309172
- Where
- Denmark
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Ole Köhler-Forsberg
Schizophrenia
A Study of Olanzapine in Patients With Schizophrenia
The primary objectives of the study is to confirm if the efficacy of intramuscular injection (IM) olanzapine 10 milligrams (mg) in patients with an exacerbation of schizophrenia with acute psychotic agitation is greater than…
- Trial name
- NCT00970281
- Testing
- Rapid-Acting Intramuscular Olanzapine
- Where
- 11 sites in Japan
- Volunteers
- 91 people
- Sponsor
- Eli Lilly and Company
COMT Gene Polymorphism
Pharmacogenetics of Cannabinoid Response
This study attempts to examine genetic influences on the effects of tetrahydrocannabinol (Δ9-THC), the active ingredient of marijuana, cannabis, "ganja", or "pot".
- Trial name
- NCT00678730
- Testing
- delta 9 tetrahydrocannabinol
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Yale University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.